MMP9 and inflammatory bowel disease: In conclusion our data (i) illustrate that mouse KO experiments need to be better controlled than published in most manuscripts up-to-now and that careful analyses of genetic background, of eventual leakiness at the mRNA and protein levels and of different environmental factors between used WT and KO mice need to be detailed, (ii) place important question marks behind the previously reported causal role of MMP-9 in murine colitis and (iii) call for scrutiny in preclinical and clinical tests of prophylactic and therapeutic MMP inhibition for IBD.